Sequoia Financial Advisors LLC lifted its holdings in Solventum Co. (NYSE:SOLV – Free Report) by 8.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,737 shares of the company’s stock after purchasing an additional 441 shares during the period. Sequoia Financial Advisors LLC’s holdings in Solventum were worth $400,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Copeland Capital Management LLC acquired a new position in shares of Solventum in the third quarter worth $26,000. Mather Group LLC. purchased a new position in shares of Solventum during the third quarter worth approximately $27,000. EverSource Wealth Advisors LLC acquired a new position in shares of Solventum in the 1st quarter valued at $30,000. Hollencrest Capital Management purchased a new stake in Solventum in the 2nd quarter valued at $25,000. Finally, Deseret Mutual Benefit Administrators acquired a new stake in Solventum during the 2nd quarter worth $25,000.
Wall Street Analyst Weigh In
SOLV has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. Piper Sandler started coverage on Solventum in a report on Monday, October 7th. They issued a “neutral” rating and a $71.00 price objective on the stock. BTIG Research assumed coverage on Solventum in a research note on Thursday, September 5th. They set a “neutral” rating for the company. Wolfe Research assumed coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. Finally, Wells Fargo & Company dropped their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $64.33.
Solventum Trading Down 0.0 %
SOLV opened at $73.19 on Monday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The stock’s 50 day simple moving average is $67.58 and its 200 day simple moving average is $61.26. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31.
Solventum (NYSE:SOLV – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.10. The firm had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.05 billion. The company’s revenue for the quarter was up .2% compared to the same quarter last year. On average, sell-side analysts anticipate that Solventum Co. will post 6.38 earnings per share for the current year.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
See Also
- Five stocks we like better than Solventum
- What is the Euro STOXX 50 Index?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Use Stock Screeners to Find Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- About the Markup Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.